Takeda doubles U.K. rep ranks to boost oncology, IBD sales

Carly Helfand

has its eye on some serious growth–and to help it get there, it's bringing its force in-house. Beginning this June, 70 contract staffers–including those on teams for and inflammatory bowel disease (IBD)–will become employees, a move that will nearly double 's in the U.K.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS